Traders should monitor the September 2026 PDUFA date for sBCC as a key catalyst; sustained revenue growth and margin expansion suggest potential for continued profitability, but small market cap and prior losses warrant caution on valuation.
Price Chart
Executive Summary
Biofrontera Inc. reported strong fourth-quarter and full-year 2025 results, with record Q4 revenue of $17.1 million (up 36% YoY) and gross margins expanding to 82.4% from 58.0% due to a favorable earnout structure after acquiring U.S. assets from Biofrontera AG. The company achieved its first profitable quarter with $5.6 million in net income, driven by lower costs and higher sales, while advancing its clinical pipeline with key FDA milestones ahead.
Key Financial Metrics
Key Facts
- Q4 2025 revenue was $17.1 million, up 36% YoY from $12.6 million in Q4 2024
- Gross margin expanded 2,440 basis points to 82.4% in Q4 2025 from 58.0% in Q4 2024
- Q4 2025 net income was $5.6 million vs. a net loss of $1.4 million in Q4 2024
- Full-year 2025 revenue grew 12% to $41.7 million; net loss narrowed to $10.5 million from $17.7 million in 2024
- Completed acquisition of U.S. Ameluz and RhodoLED assets, reducing earnout payments from 25%-35% to 12%-15% of U.S. net sales
- FDA accepted sNDA for Ameluz for sBCC with PDUFA date expected in September 2026
- Positive Phase 3 results in AK on extremities and Phase 2b data in acne
Financial Impact
Revenue increased by $4.5M YoY in Q4 and $4.4M for full year; gross profit margin improved by 24.4 percentage points in Q4, significantly enhancing profitability
Risk Factors
- Small market cap ($10M) increases volatility and sensitivity to execution risk
- Historical net losses and negative cash flow from operations (-$13.4M in 2025) raise sustainability concerns despite recent improvement
- Forward-looking statements around profitability and commercial growth are subject to execution and regulatory risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259125 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | 8-K | $1.36 | awaiting T+60 | — | $0.7846 (−42.31%) |
Aug 13, 2026 10w ago | 8-K | $1.26 | awaiting T+60 | — | $0.7846 (−37.73%) |
May 14, 2026 23w ago | Press Release | $0.9890 $1.21 | ▲ +22.35% | ▲ +18.76% | $0.7846 (−20.67%) |
May 8, 2026 24w ago | Press Release | $1.11 $1.24 | ▲ +11.71% | ▲ +7.32% | $0.7846 (−29.32%) |
Mar 19, 2026 31w ago | Press Release | $0.8560 $1.00 | ▲ +16.82% | ▲ +2.48% | $0.7846 (−8.34%) |
Feb 26, 2026 34w ago | 8-K | $0.9270 $0.7790 | ▼ −15.97% | ▼ −23.72% | $0.7846 (−15.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers